Reported 2 days ago
Chinese pharmaceutical executives expressed confidence despite reports that the Trump administration is considering restrictions on licensing for medicines developed in China. At the BioHK 2025 conference in Hong Kong, industry leaders discussed the resilience of the Chinese supply chain and emphasized strategies for diversifying markets to mitigate geopolitical risks. While shares of some Chinese drug firms dipped following the news, there was a collective belief that the impact could be managed.
Source: YAHOO